Nuo Therapeutics, Inc. 8K

Nuo Therapeutics, Inc. announced strong year-over-year revenue growth, an improved operating loss, favorable reimbursement and distribution developments, and amended loan financing in its second quarter 2026 business update.

On August 17, 2026, Nuo Therapeutics, Inc. reported its unaudited financial results for the second quarter and first half of 2026, highlighting revenue growth of over 150% versus the prior-year periods to approximately $1.77 million for the quarter and $3.07 million for the first half, an improved second quarter net operating loss of about $167,000, and sequential quarterly growth in Aurix product revenues of more than 30%, while also providing a business update on favorable Medicare reimbursement dynamics for autologous PRP therapies, the continued positive performance of its Smith+Nephew distribution arrangement including achievement of a reimbursement fee milestone, and an amended and restated loan agreement providing $675,000 of interim funding with an option to increase total borrowings under a $2 million commitment to support working capital needs as the company seeks to move toward breakeven operations.

Filing Facts

CIK

1091596

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-028109

Alert Tier

6